Literature DB >> 23919393

MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer.

Wenjing Zhang1, Qian Wang, Minglian Yu, Nan Wu, Hui Wang.   

Abstract

MiR-145 is reported to be significantly down-regulated in ovarian cancer. This study was aimed at elucidating the roles of miR-145 in regulating the biological behavior of epithelial ovarian cancer (EOC) cells. In this report, we find out that up-regulation of miR-145 in OVCAR-3 and SKOV-3 cells inhibit cell proliferation and promote cell apoptosis. We show that miR-145 directly target the c-Myc 3'-UTR. Moreover, ectopic expression of c-Myc reduces the inhibition of cell proliferation caused by miR-145 transfection. Cell cycle assay showed that up-regulation of miR-145 reduces S phase population, and restoration of c-Myc can rescue this reduction. These findings indicate that miR-145 inhibits cell proliferation and promotes cell apoptosis by targeting c-Myc 3'-UTR. Therefore, the result indicated that miR- 145 could be used as a potential therapeutic target in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23919393     DOI: 10.7785/tcrt.2012.500367

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  16 in total

1.  Serum microRNA-145 as a novel biomarker in human ovarian cancer.

Authors:  Huichao Liang; Zhipeng Jiang; Guie Xie; Yan Lu
Journal:  Tumour Biol       Date:  2015-02-27

2.  Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.

Authors:  Qing Cao; Kunlin Lu; Suiping Dai; Yan Hu; Weifang Fan
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

3.  The potential value of microRNA-145 for predicting prognosis in patients with ovarian cancer: A protocol for systematic review and meta-analysis.

Authors:  Zhen Chen; Zelan Xiao; Siheng Zeng; Zhiqiang Yan
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 4.  MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways.

Authors:  Shi-Yun Cui; Rui Wang; Long-Bang Chen
Journal:  J Cell Mol Med       Date:  2014-08-15       Impact factor: 5.310

5.  miRNAsong: a web-based tool for generation and testing of miRNA sponge constructs in silico.

Authors:  Tomas Barta; Lucie Peskova; Ales Hampl
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

6.  Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Authors:  Asfar S Azmi; Yiwei Li; Irfana Muqbil; Amro Aboukameel; William Senapedis; Erkan Baloglu; Yosef Landesman; Sharon Shacham; Michael G Kauffman; Philip A Philip; Ramzi M Mohammad
Journal:  Oncotarget       Date:  2017-07-17

7.  Apoptosis-related microRNA-145-5p enhances the effects of pheophorbide a-based photodynamic therapy in oral cancer.

Authors:  Sook Moon; Do Kyeong Kim; Jin Kim
Journal:  Oncotarget       Date:  2017-05-23

8.  miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer.

Authors:  Xin Yan; Xi Chen; Hongwei Liang; Ting Deng; Weixu Chen; Suyang Zhang; Minghui Liu; Xiujuan Gao; Yanqing Liu; Chihao Zhao; Xueliang Wang; Nan Wang; Jialu Li; Rui Liu; Ke Zen; Chen-Yu Zhang; Baorui Liu; Yi Ba
Journal:  Mol Cancer       Date:  2014-09-24       Impact factor: 27.401

9.  Brief Report: Inhibition of miR-145 Enhances Reprogramming of Human Dermal Fibroblasts to Induced Pluripotent Stem Cells.

Authors:  Tomas Barta; Lucie Peskova; Joseph Collin; David Montaner; Irina Neganova; Lyle Armstrong; Majlinda Lako
Journal:  Stem Cells       Date:  2015-10-09       Impact factor: 6.277

10.  Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.

Authors:  Charles Johannessen; Line Moi; Yury Kiselev; Mona Irene Pedersen; Stig Manfred Dalen; Tonje Braaten; Lill-Tove Busund
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.